Rapamycin inhibits mTORC1 rapidly but can disrupt mTORC2 with prolonged or high exposure, potentially leading to insulin resistance, immune suppression, and endothelial damage—serious risks for longevity seekers. Intermittent low dosing minimizes mTORC2 impact while preserving benefits like autophagy induction. Experts like Peter Attia and Matt Kaeberlein advocate pulsed protocols to balance these effects. How Does…

In 2026, the discussion around longevity has moved from "What is the best pill?" to "How do we balance the pathways?" The debate over Rapamycin vs. Metformin for longevity has reached a turning point in 2026. While both molecules dominated early geroscience discussions, recent meta-analyses and clinical data now distinguish between "fringe benefits" and "fundamental…

For many in the longevity community, the six-month mark is the "Gold Standard" milestone. It is the point where the initial placebo effects fade, and the real biological data—from lipid panels to biological age clocks—begins to tell a definitive story. While clinical trials like the ERAP trial for Alzheimer’s and the Kraig et al. study…

For many people interested in living longer, the goal is simple: avoid the "Big Four" diseases of aging. At the top of that list is cancer. Modern science is moving away from just treating cancer after it appears and toward Rapamycin and cancer prevention as a way to stop the disease before it even starts.…

Rapamycin and Metabolic Effects: Blood Sugar, Cholesterol, and What to Monitor The pursuit of human longevity has transitioned from speculative "elixirs" to the rigorous science of geroprotection, with the mechanistic target of rapamycin (mTOR) pathway serving as a central hub. While Rapamycin is the most robust pharmacological intervention for extending lifespan in model organisms, its…

Navigating the landscape of geroprotectors requires a shift from traditional disease treatment to proactive biological optimization. Rapamycin dosing for longevity has moved beyond theoretical mouse models and into the clinics of specialty practitioners, yet the transition from a daily transplant drug to an intermittent anti-aging protocol requires precision to maximize autophagy while avoiding metabolic pitfalls.…

For decades, the search for a true "longevity pill" was considered more science fiction than science. However, the discovery of the mTOR pathway and its inhibition by a soil-derived molecule called rapamycin has shifted that perspective. While animal studies have long shown that rapamycin can extend lifespan by up to 60%, the question of whether…

From longevity communities to advanced clinical research, rapamycin is emerging as one of the most promising tools for supporting healthy aging in women. Today, both scientific discoveries and real-world experiences are shaping a hopeful new chapter in women’s health and longevity. A Growing Movement: Women Turning to Rapamycin What excites me most is not only…

Rapamycin has long been studied as a potential rapamycin anti aging therapy—something explored in detail in resources like this longevity overview. But in 2025, the spotlight is shifting toward new and unexpected research directions—far beyond its classic role in slowing aging. Here are some of the most intriguing and lesser-known findings emerging this year, especially…

Rapamycin has gone from being a life-saving drug for transplant patients to one of the most intriguing candidates for slowing aging. As more research uncovers new rapamycin benefits, scientists are now exploring its role in cellular rejuvenation, metabolic repair, and even reproductive health. Beyond the headlines, new discoveries continue to shape how we think about…